Orum Therapeutics files registration statement for Kosdaq listing

Orum Therapeutics has submitted a registration statement to the Financial Services Commission to go public on the Kosadq market.

Orum Therapeutics is a leading biopharmaceutical company in the field of degrader-antibody conjugates (DACs) based on its dual precision-targeted proteolytic approach, TPD².

DACs are emerging as a new generation of therapeutics that use antibodies to selectively deliver targeted proteases to target cells to degrade target proteins within the cell. Through its TPD² approach, Orum Therapeutics has developed treatments based on the GSPT1 degradation mechanism and various clinical-stage programs.

The company also has its linker technology, TPD²-PROTAb.

In 2023, Orum Therapeutics posted sales of 135.4 billion won ($101.5 million), operating income of 95.6 billion won, and net income of 68.2 billion won.

The company plans to issue 3 million shares, with an offering price per share ranging from 30,000 to 36,000 won. Based on the lower end of the offering price, total proceeds will likely be about 90 billion won, including issuance fees and other expenses.

Orum Therapeutics will finalize the offering price by conducting demand forecasts for domestic and foreign institutional investors from Oct. 24 to 30 and conduct general subscriptions on Nov. 5 and 6. Korea Investment & Securities is the lead underwriter.

(Caption)

Orum Therapeutics’ corporate identity